Natural hormone replacement therapy with a functioning ovary after the menopause: dream or reality?
Publication date: Available online 30 June 2018Source: Reproductive BioMedicine OnlineAuthor(s): Jacques Donnez, Marie-Madeleine DolmansAbstractAt the dawn of humanity, it was rare to live beyond the age of 35 years, so the ovary was intended to function for a woman's entire life. Nowadays, it is not unusual for women to live into their 80s. This means that many of them spend 30–40% of their lives in the menopause at increased risk of various conditions associated with an absence of oestrogens (cardiovascular disease, bone mineral density loss). Reimplantation of frozen–thawed ovarian tissue is able to restore long-term ovarian endocrine function that can persist for more than 7 years (12 years if the procedure is repeated). If ovarian tissue reimplantation is capable of restoring ovarian activity after menopause induced by chemotherapy, radiotherapy, surgery, or a combination of all three, why not propose it to recover sex steroid secretion after natural menopause and prevent menopause-related conditions in the ageing population? In this application, the graft site could be outside the pelvic cavity, e.g., forearm or rectus muscle. Could ovarian tissue freezing at a young age followed by reimplantation upon reaching menopause be the anti-ageing therapy of the future? Sufficient existing evidence now surely merits serious debate.
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients at ASCO 2018. Author: obr Added: 07/18/2018
The objective of this study was to investigate the effect of a horticultural therapy program on reducing middle-aged women's depression and anxiety and improving their self-identity. DESIGN AND SETTING: Participants were 36 women aged 40-59 years who attended the D Culture Center in Incheon, South Korea (control, n = 18; experimental, n = 18). INTERVENTION: The study was conducted in July-August 2017; the experimental group participated twice/week for 12 sessions. MAIN OUTCOME MEASURES: The Menopause Symptom Index, Self-rating Depression Scale, State-Trait Anxiety Inventory, and Dignan Ego-identity S...
Helen Owen said women going through a similar experience should seek specialist help.
(The North American Menopause Society (NAMS)) Heart disease is still the number one killer of US women, and hormone therapy remains a top treatment for menopause symptoms. A new study connects these two facts to demonstrate little effect of hormone therapy on artery thickness as a precursor to heart disease. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
A woman who went through the menopause at 29 says she "missed out" on treatment options.
Herb Formula ZhenRongDan Balances Sex Hormones, Modulates Organ Atrophy, and Restores ERα and ERβ Expressions in Ovariectomized Rats. Evid Based Complement Alternat Med. 2018;2018:5896398 Authors: Zhang X, Chen Q, Chen B, Wang F, Chen XH Abstract Herb mixtures are widely used for treatment of the menopausal syndrome long before the hormonal therapy. However, there is insufficient data for herb remedies in treating menopausal syndromes. Here we aim to investigate the effect of ZhenRongDan (ZRD) in balancing female hormones, regulating expression of estrogen receptors (ERs), and preventing org...
Conditions: Relationship Between Menopause and Urinary Functional Disorders; Relationship Between Overweight and Urinary Functional Disorders; Relationship Between Surgical Antecedent and Urinary Functional Disorders; Relationship Between Gestity and Urinary Functional Disorders Intervention: Other: Female urinary incontinence Sponsor: University Hospital, Clermont-Ferrand Completed
This important article assesses the overall cancer risk among contemporary menopausal hormone therapy (MHT) users, based on a nationwide Swedish population –based cohort study in 290,186 women using systemic MHT from July 2005 until December 2012.
Estrogen deficiency is linked to changes in several physiological processes, but the extent to which it associates with cognitive changes in menopause context is controversial.
Abstract Approximately half of all human cancers contain mutations in the TP53 tumor suppressor. In addition to mutations, there are single nucleotide polymorphisms (SNPs) in TP53 that can dampen p53 function, and can increase cancer risk and decrease the efficacy of cancer therapy. Approximately 6% of Africans and 1% of African-Americans express a p53 allele with a serine instead of proline at position 47 (Pro47Ser, or S47). The S47 variant is associated with increased breast cancer risk in pre-menopausal African Americans, and in a mouse model for the S47 variant, mice are predisposed to spontaneous cancers. We ...